FSHD Molecular Characterization

Description

To characterize the clinical and molecular phenotype of FSHD.

Conditions

Facio-Scapulo-Humeral Dystrophy

Talk to us

Study Overview

On this page

Study Details

Study overview

To characterize the clinical and molecular phenotype of FSHD.

Clinical and Molecular Characterization of Facioscapulohumeral Muscular Dystrophy (FSHD)

FSHD Molecular Characterization

Condition
Facio-Scapulo-Humeral Dystrophy
Intervention / Treatment

-

Contacts and Locations

Columbus

The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States, 43205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 13 years or older
  • * Genetically proven FSHD1 or FSHD2 as determined by the investigators
  • * Inability to complete an MRI scan (Adults only).
  • * Other medical or cognitive issues that, in the opinion of the examiner, preclude accurate functional assessment.

Ages Eligible for Study

13 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Nationwide Children's Hospital,

Kevin Flanigan, MD, PRINCIPAL_INVESTIGATOR, Nationwide Children's Hospital

Study Record Dates

2026-03-05